Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions

  |  Issue: December 2024  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Burmester GR, Cohen SB, Deodhar A, et al. Safety of upadacitinib across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis encompassing 15,000 patient-years of clinical trial data [POS0894]. Ann Rheum Dis. 024;83:1137–1138.
  2. Highlights of prescribing information: Rinvoq (upadacitinib) extended-release tablets. U.S. Food & Drug Administration. 2023 Apr 26.

Related Articles
    Andrew Brookes / Image Source on Offset

    Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    The Heterogeneity of Psoriatic Arthritis

    SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.